Receptor for Advanced Glycation End Products (RAGE) Ligand Axis as a Mediator of Inflammation and Oxidative Stress in Cancer: Implications for Cancer Progression and Therapeutic Targeting.
Level 5 - mechanism / opinion, no new human data
Narrative review of biological mechanisms with no original human empirical data.
PubMed 42283171 · doi:10.2174/0113816128488085260604051040
What was done
This narrative review summarizes literature on the Receptor for Advanced Glycation End Products (RAGE) ligand axis in cancer biology. It describes RAGE ligand interactions (including AGE, HMGB1, and S100), upstream activation via NF-κB, downstream impacts on oxidative stress, inflammation, tumor microenvironment modulation (MDSCs, TAMs, p53, PTEN), paradoxical protective functions in normal lung tissue, and prospective therapeutic strategies.
What was found
The abstract provides no numerical data or quantitative outcomes. It describes qualitatively that the RAGE-ligand axis sustains inflammatory and oxidative stress cycles, drives key oncogenic processes (proliferation, angiogenesis, metastasis, invasion), inhibits antitumor immunity, and exhibits organ-specific paradoxical tumor-suppressive behavior in normal lung physiology.
Why it matters
It outlines mechanistic pathways connecting RAGE-driven chronic inflammation and immune suppression to cancer progression, mapping potential molecular targets for therapeutic intervention.
Limits
The paper is a narrative literature review lacking primary empirical data, systematic review methodology, or meta-analytic quantification. No clinical trial outcomes, patient sample sizes, or quantitative risk estimates are reported.
Cited by
- supports Glycated proteins are highly inflammatory in the human body.